Assessment of HER2 Status of Metastatic Breast Carcinoma on Cell Block Preparations of Fine Needle Aspirates is Unreliable

Author(s):  
Vignesh Shanmugam ◽  
Syed Hoda ◽  
Thomas Dilcher ◽  
Adam Pacecca ◽  
Rana Hoda
2010 ◽  
Vol 39 (9) ◽  
pp. 681-685 ◽  
Author(s):  
Franco Fulciniti ◽  
Luciano Pezzullo ◽  
Maria Grazia Chiofalo ◽  
Daniela Butera ◽  
Nunzia Simona Losito ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11540-e11540
Author(s):  
Ummugul Uyeturk ◽  
Burcin Budakoglu ◽  
Ibrahim Turker ◽  
Kaan Helvaci ◽  
Ozlem Uysal Sonmez ◽  
...  

e11540 Background: Metastatic breast cancer is a heterogenous disease. There are several subgroups according to pathological, biological and molecular behaviours of the tumor. Recurrent metastatic breast carcinoma (RMBC) and upfront metastatic breast carcinoma (UMBC) may differ according to clinical and prognostic characteristics. Intrinsic genetic heterogeneity may be responsible for these differences. To date, little is known about the clinical features and outcome of patients with UMBC. Methods: Patients were considered to have UMBC if patients were admitted to the clinics with stage IV disease. Patients were considered to have RMBC if metastases had developed during followup for localized breast carcinoma. Between September 2007 and May 2011, 102 of 2478 (4.1%) UMBC patients who was admitted to Department of Medical Oncology Clinic, was included in this retrospective trial. Patients’ characteristics, treatment schedules and survival data were evaluated. Results: All patients were female. Median age was 50.0 (range: 26-90). More than half of patients (58.8%) were postmenopausal. Frequent histological type was invasive ductal carcinoma (89.2%). Most of the patients had grade 3 (57.8%) tumor. Hormone receptor (HR) and HER2 positivity were76.5% and 42.2%, respectively. Metastatic sites were visceral, isolated bone-soft tissue and combination in 20%, 42% and 37%, respectively. Most of visceral metastatic patients were HR negative and HER2 positive. Median PFS and OS were 30 and 66 months, respectively. Both PFS and OS were affected from HR status, HER2 status, sites of metastatic disease and chemotherapy (log-rank p=0.006, 0.04, 0.02, 0.004, 0.03 and log-rank p= 0.04, 0.04, 0.01, 0.03, 0.01 respectively). Both PFS and OS were not affected by age, menopausal status, performance status, histology and grade of the tumor. OS were longest in patients group who received chemotherapy (76 months) and shortest in patients group who received chemotherapy and targeted therapy combinations (23 months). Conclusions: Factors affecting survival were comparable to previous studies in UMBC patient population similiar to results RMBC studies. This finding should be confirmed with prospective trials in larger study populations.


2014 ◽  
Vol 138 (4) ◽  
pp. 553-558 ◽  
Author(s):  
Adria K. Hartman ◽  
Blythe K. Gorman ◽  
Subhendu Chakraborty ◽  
Dina R. Mody ◽  
Mary R. Schwartz

Context.—Validation of new methodologies for determining human epidermal growth factor receptor 2 gene (HER2/neu) amplification status is crucial for advancing the standard of care and determining treatment for patients with primary and/or metastatic breast carcinoma. Objective.—To compare results of HER2/neu gene amplification status by 2-color chromogenic in situ hybridization (ISH) on cell block material to HER2/neu status by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) in the corresponding resection specimen or previous biopsy specimen. Design.—Formalin, thrombin, and Cellient cell blocks were prepared from cytologic samples obtained from resection specimens from 27 patients with invasive breast carcinoma. In situ hybridization was performed on cell block sections from 18 of the collected cases, on both the Ventana BenchMark ULTRA and the Ventana BenchMark XT, and the HER2/neu gene amplification status was determined. This was then compared to the HER2/neu status by IHC and/or FISH in the resection specimen or previous biopsy specimen. Results.—Comparison of HER2/neu status by ISH on the quantifiable cell block sections showed 100% correlation with the HER2/neu status determined by IHC or FISH in the corresponding histologic specimens. The results from thrombin and formalin cell blocks were statistically superior to the results from Cellient cell blocks on both Ventana instruments. Conclusions.—While further validation and study are needed, preliminary results show that the HER2/neu gene amplification status of breast carcinomas can reliably be determined on thrombin and formalin cell block material by using ISH. More consistent staining and better signal integrity was obtained with the Ventana BenchMark ULTRA than the BenchMark XT.


2016 ◽  
Vol 44 (12) ◽  
pp. 980-986 ◽  
Author(s):  
Issam M. Francis ◽  
Preeta Alath ◽  
Sara S. George ◽  
Mohammed Jaragh ◽  
Ayesha Al Jassar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document